Type I ovarian cancer, which includes low‐grade serous carcinoma, endometrioid carcinoma, clear cell carcinoma, and mucinous carcinoma, has been shown to exhibit KRAS, BRAF, PI3KCA, and PTEN mutations (Shih Ie & Kurman, 2004). This evidence concerns the gene BRAF and clear cell adenocarcinoma.